September 2023, Vol 4, No 3

As we approach the fall season, it is wonderful to reflect on some of the amazing research presented this year, most recently at the ASCO 2023 annual meeting. One of the major highlights of ASCO this year included the results of HER2/neu-directed novel therapies in biliary cancer. Shubham Pant, MD, MBBS, from MD Anderson Cancer Center, presented the results of the HERIZON-1 clinical trial of the bispecific antibody zanidatamab in HER2/neu-expressing biliary cancers.

HRQOL in Patients With Advanced BTC Who Received Pembrolizumab With GemCis in the KEYNOTE-966 study

ASCO Highlights

Researchers explore the impact of gemcitabine/cisplatin plus pembrolizumab on patient health-related quality of life in a subanalysis of the KEYNOTE-966 study.

CCF Celebrates Major Milestone in Connecting Patients and Caregivers to Mentorship Program

CCF Corner

September 2023, Vol 4, No 3

The Cholangiocarcinoma Foundation (CCF) is celebrating the 1000th mentor–mentee match and 6 years of their mentoring program, CholangioConnect. CCF has developed unique resources to help patients and caregivers navigate their healthcare journeys.

Encourage Your Patients to Participate! Actively Recruiting US-Based Clinical Trials in CCA September 2023

Ongoing Trials in CCA

September 2023, Vol 4, No 3

This new CCA News feature aims to provide an ongoing list of US-based clinical trials that are actively recruiting for clinicians to use in discussions with their patients to encourage enrollment. September 2023

Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC: The ADJUBIL Study

ASCO Highlights

September 2023, Vol 4, No 3

Researchers in the ADJUBIL study plan to assess the clinical activity of the immunotherapies durvalumab and tremelimumab with or without capecitabine in patients with resectable biliary tract cancer in the adjuvant setting.

SGNTUC-019: A Phase 2 Study of Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC

ASCO Highlights

September 2023, Vol 4, No 3

Basket study investigated targeted therapies as second-line treatment for patients with biliary tract cancer who are HER2-positive.

Rucaparib and Nivolumab as Maintenance Therapy Following Chemotherapy in Patients With Advanced BTC: BilT-02

ASCO Highlights

September 2023, Vol 4, No 3

Researchers are investigating novel combination therapies, including immunotherapies and poly-ADP ribose polymerase (PARP) inhibitors, to improve survival in patients with biliary tract cancer; here, the BilT-02 study is summarized.

Results From HERIZON-BTC-01: Zanidatamab in Previously Treated HER2-Amplified BTC

ASCO Highlights

September 2023, Vol 4, No 3

Preliminary results from the phase 2b HERIZON-BTC-01 study investigating the efficacy of zanidatamab in patients with HER2-positive biliary tract cancer are presented.

Using ctDNA as a Predictive Biomarker in Patients With CCA: Subanalysis of the STAMP Trial

ASCO Highlights

September 2023, Vol 4, No 3

A subanalysis of the STAMP trial examines the clinical impact of using circulating tumor DNA for detecting molecular residual disease and monitoring in patients with CCA in the adjuvant setting.

BILCAP Investigators Explore Alterations in Cancer Driver Genes and Other Mutations in Patients With BTC

ASCO Highlights

September 2023, Vol 4, No 3

The researchers found that EGFR amplifications and FGFR3 fusions may be important predictive biomarkers in biliary tract cancer (BTC) and may serve as a future target for systemic anticancer therapy in patients with BTC.

September 2023, Vol 4, No 3

Subscribe Today!

I'd like to receive:

Stay In The Know

September 2023, Vol 4, No 3

Page 1 of 2

Subscribe Today!

I'd like to receive:

Stay In The Know